Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04232215 · ClinicalTrials.gov registry record · NA
Medical Grade, Smartphone-based, Fetal Heart Rate Monitor for Outpatient Use
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT04232215: Completed NA study, sponsored by Mayo Clinic.
NCT04232215 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04232215, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
Researchers are assessing the ease of use and accuracy of the HeraBEAT™ device, a new device used with a smartphone to monitor fetal heart rate during pregnancy.
Primary Outcome
Measured using the self-reported System Usability Scale (SUS) on 10 items, each on a scale from 1 to 5 (1 = strongly disagree and 5= strongly agree). A composite score is calculated with a range of 0-100 where higher values indicated a high usability of device, whereas lower scores indicate less usability of the device.
Interventions
- DEVICE HeraBEAT™
- DEVICE Doppler fetal heart rate monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2022-08-31 |
| Phase | NA |
What the finished NCT04232215 record still lists
NCT04232215 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which HeraBEAT™ is the first listed.
NCT04232215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04232215 about?
NCT04232215 is a clinical study titled "Medical Grade, Smartphone-based, Fetal Heart Rate Monitor for Outpatient Use". Researchers are assessing the ease of use and accuracy of the HeraBEAT™ device, a new device used with a smartphone to monitor fetal heart rate during pregnancy.
What is the current status of trial NCT04232215?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2021-02-03. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT04232215?
The interventions under investigation include: HeraBEAT™ (DEVICE), Doppler fetal heart rate monitor (DEVICE).
Who is sponsoring clinical trial NCT04232215?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04232215's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI